NASDAQ:ACHV Achieve Life Sciences (ACHV) Stock Price, News & Analysis $6.83 -0.36 (-5.01%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$6.83 0.00 (-0.06%) As of 10/30/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Achieve Life Sciences Stock (NASDAQ:ACHV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Achieve Life Sciences alerts:Sign Up Key Stats Today's Range$6.57▼$7.2950-Day Range$6.38▼$8.4952-Week Range$2.62▼$8.64Volume1.38 million shsAverage Volume1.33 million shsMarket Capitalization$702.82 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingBuy Company Overview Achieve Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cytisinicline, a therapy designed to help adults quit smoking and overcome nicotine addiction. Cytisinicline is an oral, plant-based small molecule that partially activates nicotinic acetylcholine receptors, with the goal of reducing nicotine cravings and withdrawal symptoms. The company has evaluated cytisinicline in clinical studies involving adults who smoke cigarettes, including trials assessing smoking cessation and cessation of electronic cigarette use. Achieve has advanced the product through late-stage development in the United States and has worked toward regulatory approval. Cytisinicline is not an approved product in the United States, and the company’s activities remain centered on clinical development and commercialization planning. Achieve Life Sciences was formed through the combination of Achieve Pharma and OncoGenex Pharmaceuticals, a transaction completed in 2017. The company is headquartered in Vancouver, British Columbia, and maintains operations in the United States. Its leadership has included John Bencich as chief executive officer and members of its medical and clinical development team focused on addiction medicine and regulatory strategy.AI Generated. May Contain Errors. Read More Achieve Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreACHV MarketRank™: 2.60054666146 of 5 starsAchieve Life Sciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 462nd out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAchieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAchieve Life Sciences has a consensus price target of $15.50, representing about 126.9% upside from its current price of $6.83.Amount of Analyst CoverageAchieve Life Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Achieve Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Achieve Life Sciences are expected to grow in the coming year, from ($0.92) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achieve Life Sciences is -4.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achieve Life Sciences is -4.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAchieve Life Sciences has a P/B Ratio of 17.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Achieve Life Sciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.62% of the float of Achieve Life Sciences has been sold short.Short Interest Ratio / Days to CoverAchieve Life Sciences has a short interest ratio ("days to cover") of 13.85, which indicates bearish sentiment.Change versus previous monthShort interest in Achieve Life Sciences has recently increased by 1.90%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAchieve Life Sciences does not currently pay a dividend.Dividend GrowthAchieve Life Sciences does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.68 News SentimentAchieve Life Sciences has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Achieve Life Sciences this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows6 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Achieve Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $175,115.00 in company stock.Percentage Held by Insiders1.80% of the stock of Achieve Life Sciences is held by insiders.Percentage Held by Institutions33.52% of the stock of Achieve Life Sciences is held by institutions.Read more about Achieve Life Sciences' insider trading history. Receive ACHV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACHV Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), InflaRx (IFRX) and Achieve Life Sciences (ACHV)October 25, 2026 | theglobeandmail.comAchieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?October 24, 2026 | americanbankingnews.comLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gold, and other assets. The hour long session answers the question every investor faces: when to buy, when to sell, or when to simply hold steady. Sessions run every day, including evenings and early mornings, so there's a slot that fits any schedule.October 31 at 1:00 AM | The Cycle Code (Ad)Analysts Are Bullish on These Healthcare Stocks: Achieve Life Sciences (ACHV), AngioDynamics (ANGO)October 23, 2026 | theglobeandmail.comAchieve's Cytisinicline Shows 31% Smoking And Vaping Cessation Rate At One Year; Stock UpOctober 21, 2026 | rttnews.comAchieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026October 21, 2026 | globenewswire.comAchieve Life Sciences, Inc. (NASDAQ:ACHV) Stock Has Average Target Price of $15.50 According to BrokeragesOctober 21, 2026 | americanbankingnews.comAchieve Life Sciences, Inc. Announces Appointment of Kaitlyn Tuson as Senior Vice President, Marketing and CommunicationsOctober 8, 2026 | marketscreener.comMSee More Headlines ACHV Stock Analysis - Frequently Asked Questions How have ACHV shares performed this year? Achieve Life Sciences' stock was trading at $4.97 at the beginning of the year. Since then, ACHV shares have increased by 37.4% and is now trading at $6.83. How were Achieve Life Sciences' earnings last quarter? Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted its quarterly earnings data on Tuesday, August, 11th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.64. When did Achieve Life Sciences' stock split? Shares of Achieve Life Sciences reverse split before market open on Friday, July 31st 2020.The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Achieve Life Sciences' major shareholders? Achieve Life Sciences' top institutional shareholders include Simplify Asset Management Inc., Profund Advisors LLC (0.03%) and SLT Holdings LLC (0.01%). Insiders that own company stock include Thomas Braxton King, Richard Alistair Stewart, Mark K Oki, Cindy Jacobs, Jaime Xinos and Jerry Wan. View institutional ownership trends. How do I buy shares of Achieve Life Sciences? Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Achieve Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Achieve Life Sciences investors own include Advanced Micro Devices (AMD), Micron Technology (MU), NVIDIA (NVDA), Plug Power (PLUG), Gilead Sciences (GILD), Alibaba Group (BABA) and NIO (NIO). Company Calendar Last Earnings8/11/2026Today10/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ACHV's financial health is in the Green zone, according to TradeSmith. ACHV has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ACHV CIK949858 Webachievelifesciences.com Phone(425) 686-1500Fax425-686-1600Employees28Year Founded1995Price Target and Rating Average Price Target for Achieve Life Sciences$15.50 High Price Target$19.00 Low Price Target$12.00 Potential Upside/Downside+126.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$54.65 million Net MarginsN/A Pretax MarginN/A Return on Equity-511.12% Return on Assets-82.35% Debt Debt-to-Equity Ratio0.87 Current Ratio0.95 Quick Ratio0.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book17.08Miscellaneous Outstanding Shares102,902,000Free Float101,050,000Market Cap$702.82 million OptionableOptionable Beta2.30 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ACHV) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
